Antibiotic prophylaxis in neutropenic patients

Israel Medical Association Journal

Volumn 9, Issue 6, 2007, Pages 460-462

  Gafter Gvili, Anat ^a,b   Paul, Mical ^a,b   Fraser, Abigail ^a   Leibovici, Leonard ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antibiotics; Fluroquinolones; Neutropenia; Prophylaxis

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; LEVOFLOXACIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN;

ACUTE LEUKEMIA; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BACTEREMIA; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CROSS RESISTANCE; DRUG CHOICE; DRUG COST; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HUMAN; LYMPHOMA; META ANALYSIS; MULTIPLE CYCLE TREATMENT; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; SOLID TUMOR; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTEREMIA; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; NEUTROPENIA;

EID: 34250863884     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Bodey GP, Buckley M, Sathe YS, Friereich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
2. Schimpff SC. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 1986;80(Suppl 5c):13-20.
3. Lucas KG, Brown AE, Armstrong D. The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer 1996;77:791-8.
4. Viscoli C, Castagnola E. Planned progressive antimicrobial therapy in neutropenic patients. Br J Haematol 1998;102:879-88.
5. Paul M, Leibovici L. Systematic reviews and meta-analysis of febrile neutropenia. Mayo Clin Proc 2005;80:1122-5.
6. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005;142:979-95.
7. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005;353:977-87.
8. Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005;353:988-98.
9. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 1994;330:1240-1.
10. Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994;38:681-7.
11. Baum HV, Franz U, Geiss HK. Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients. Infection 2000;28: 278-81.
12. Razonable RR, Litzow MR, Khaliq Y, Piper KE, Rouse MS, Patel R. Bacteremia due to viridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis 2002;34:1469-74.
13. Kern WV, Klose K, Jellen-Ritter AS, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropaenic patients with leukaemia. Eur J Clin Microbiol Infect Dis 2005;24:111-18.
14. Reuter S, Kern WV, Sigge A, et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 2005;40:1087-93.
15. Martino R, Subira M, Altes A, et al. Effect of discontinuing prophylaxis with norfloxacin in patients with haematologic malignancies and severe neutropaenia. A matched case-control study of the effect on infectious morbidity. Acta Haematol 1998;99:206-11.
16. Delarive P, Baumgartner JD, Glauser MP, Cometta A. Evaluation de la prophylaxie antibiotique chez les patients neutropéniques avec hémopathie maligne. Schweiz Med Wochenschr 2000; 130:1837-44.
17. Gomez L, Garau J, Estrada C, et al. Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichla coli. Cancer 2003;97:419-24.
18. Tjan-Heijnen VC, Postmus PE, Ardizzoni A, et al. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol 2001;12:1359-68.
19. Greenberg D, Moser A, Yagupsky P, et al. Microbiological spectrum and susceptibility patterns of pathogens causing bacteraemia in paediatric febrile neutropenic oncology patients: comparison between two consecutive time periods with use of different antibiotic treatment protocols. Int J Antimicrob Agents 2005;25: 469-73.
20. Elishoov H, Or R, Strauss N, Engelhard D. Nosocomial colonization, septicemia, and Hickman/Broviac catheter-related infections in bone marrow transplant recipients. A 5-year prospective study. Medicine (Baltimore) 1998;77:83-101.
21. Fadda G, Nicoletti G, Schito GC, Tempera G. Antimicrobial susceptibility patterns of contemporary pathogens from uncomplicated urinary tract infections isolated in a multicenter Italian survey: possible impact on guidelines. J Chemother 2005;17:251-7.
22. Luzzaro F, Vigano EF, Fossati D, et al. Prevalence and drug susceptibility of pathogens causing bloodstream infections in northern Italy: a two-year study in 16 hospitals. Eur J Clin Microbiol Infect Dis 2002;21:849-55.